Using a cohort of fixed breast cancer samples, immunohistochemistry detected 3 in 39 ER+ samples, 2 in 31 ER-/Her-2+ samples, and 28 in 43 TNBC samples were positive for ART3 expression. Here, ESR1 is linked to breast cancer.